Proper storage is essential to maintain the medication's effectiveness
As of this writing, the FDA has not yet formally published the updated Category 2 list following Secretary Kennedy's February 27, 2026 announcement
The cost of ongoing treatment factors into long-term planning and influences decisions about target weight and maintenance strategies
Ongoing clinical trials are exploring the long-term effects of retatrutide on various health outcomes, including cardiovascular risk factors and quality of life improvements
One may feel a clear difference in punch, throttle response, or consistency under load
Three generations of incretin agonists: understanding the evolution of retatrutide vs tirzepatide vs semaglutide The recent pharmacological history of obesity treatment can be summarized in three successive stages, each adding a new mechanism to the previous one